XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2 accelerates the recovery of mild to moderate COVID-19 patients and keeps its neutralizing activity against Omicron and its subvariants DOI Creative Commons
Garyphallia Poulakou, Pierre‐Joseph Royer,

Nikolai Evgeniev

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 19, 2023

ABSTRACT Background XAV-19 is a glyco-humanized swine polyclonal antibody targeting SARS-CoV-2. The safety and clinical efficacy of was investigated in patients with WHO score 2 to 4 the 7-point ordinal scale. activity against Omicron its subvariants assessed vitro . Methods A phase II/III, multicentric randomized double-blind placebo-controlled, trial conducted evaluate inpatients COVID-19 requiring or not oxygen therapy outpatients (EUROXAV trial, NCT04928430 ). Most were vaccinated. primary endpoint proportion an aggravation within 8 days after treatment. Binding neutralization by ELISA whole virus assay. Results Patients received either 150mg (N=139) placebo (N=140). Low enrolment forced premature termination. well tolerated. No difference endpoint, nor improvement at day (secondary endpoint) observed between groups. For therapy, reduced time significantly (7 vs 14 p=0.0159). Neutralizing BA.2, BA2.12.1, BA.4/5 BQ1.1 shown vitro. Conclusions did reduce patients. While it bring any benefit oxygen, for (WHO 3). These preliminary data might indicate therapeutic potential mild moderate supplementation anti-SARS-CoV-2 neutralizing antibodies.

Language: Английский

Novel neutralizing mouse-human chimeric monoclonal antibodies against the SARS-CoV-2 receptor binding domain DOI
Ahmad Ghorbani,

Faezeh Maghsood,

Hamidreza Yadegari

et al.

Journal of Medical Microbiology, Journal Year: 2023, Volume and Issue: 72(6)

Published: June 30, 2023

Introduction. Neutralizing antibodies have been widely used for the prophylaxis and treatment of COVID-19.Hypothesis. The major target these neutralizing is receptor-binding domain (RBD) viral spike protein.Aim. In present study, we developed characterized three chimeric mouse-human mAbs potential therapeutic purposes.Methodology. Light heavy chain variable region genes mouse (m4E8, m3B6, m1D1) were amplified ligated to human Cγ1 Cκ constant by PCR. After cloning into a dual promoter mammalian expression vector, final constructs transiently expressed in DG-44 cells purified ELISA Western blotting. potency was determined different virus neutralization tests including sVNT, pVNT, cVNT.Results. All recombinant display regions are able specifically bind RBD SARS-CoV-2 with affinities comparable parental mAbs. blot analysis showed similar epitope specificity profiles both results (sVNT, cVNT) indicate that c4E8 had most potent activity IC50 values 1.772, 0.009, 0.01 µg ml-1, respectively. displayed pattern reactivity protein variants concern (VOC) tested, alpha, delta, wild-type.Conclusion. potentially valuable tools disease control.

Language: Английский

Citations

1
Diagnosis, Characterization and Treatment of Emerging Pathogens DOI Creative Commons
Shengxi Chen

Microorganisms, Journal Year: 2023, Volume and Issue: 11(8), P. 2032 - 2032

Published: Aug. 8, 2023

Emerging infectious diseases are perhaps the most rapidly spreading [...]

Language: Английский

Citations

1
Recurrent COVID-19 Infection in a Refractory/Classical Hodgkin's Lymphoma Patient Undergoing Autologous Stem Cell Transplantation: A Case Report DOI Open Access
Munerah Hamed, Doaa Alamoudi

Cureus, Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 13, 2023

Patients with challenging hematological malignancies like classic Hodgkin lymphoma (cHL) can be further complicated when affected by a concurrent coronavirus disease-2019 (COVID-19) infection and often face unique complex management outcomes. In this case report, we describe refractory or relapsed patient recurrent of COVID-19 three times preceding chemotherapy. A 52-year-old female presented to our hospital second incidence complaint fever, anorexia, night sweats, abdominal lymphadenopathy, for which she was diagnosed mixed cellularity lymphoma. Three weeks later, in consideration her manifestation lung disease, due past medical history airway hypersensitivity abnormal pulmonary function test along testing positive COVID-19, started the first-line chemotherapy brentuximab vedotin, doxorubicin, vinblastine, dacarbazine regimen, commonly referred as Bv-AVD, without bleomycin. After six cycles chemotherapy, at end treatment, positron emission tomography/computed tomography (PET/CT) revealed progression nodes abdomen development new lymphadenopathy chest right supraclavicular region. Hence, it considered Hodgkin’s lymphoma, salvage therapy. She on brentuximab/bendamustine (BvB). Follow-up evaluations after two BvB continued show newer lesions sub-diaphragmatic area, internal mammary, lymph nodes. Therefore, switched pembrolizumab immunotherapy, PD-1 inhibitor. four monotherapy, PET/CT showed significant improvement complete molecular response (CMR). Then, admitted high-dose therapy/autologous stem cell transplantation (HDT/ASCT) collecting cells. PET/CT: months post-ASCT, CMR Deauville score 1. The maintenance afterward. Currently, is healthy doing well. patients may experience compromised viral elimination prolonged period infection, also worsen symptoms outcomes entitle them comprehensive extended care.

Language: Английский

Citations

1
XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2 accelerates the recovery of mild to moderate COVID-19 patients and keeps its neutralizing activity against Omicron and its subvariants DOI Creative Commons
Garyphallia Poulakou, Pierre‐Joseph Royer,

Nikolai Evgeniev

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 19, 2023

ABSTRACT Background XAV-19 is a glyco-humanized swine polyclonal antibody targeting SARS-CoV-2. The safety and clinical efficacy of was investigated in patients with WHO score 2 to 4 the 7-point ordinal scale. activity against Omicron its subvariants assessed vitro . Methods A phase II/III, multicentric randomized double-blind placebo-controlled, trial conducted evaluate inpatients COVID-19 requiring or not oxygen therapy outpatients (EUROXAV trial, NCT04928430 ). Most were vaccinated. primary endpoint proportion an aggravation within 8 days after treatment. Binding neutralization by ELISA whole virus assay. Results Patients received either 150mg (N=139) placebo (N=140). Low enrolment forced premature termination. well tolerated. No difference endpoint, nor improvement at day (secondary endpoint) observed between groups. For therapy, reduced time significantly (7 vs 14 p=0.0159). Neutralizing BA.2, BA2.12.1, BA.4/5 BQ1.1 shown vitro. Conclusions did reduce patients. While it bring any benefit oxygen, for (WHO 3). These preliminary data might indicate therapeutic potential mild moderate supplementation anti-SARS-CoV-2 neutralizing antibodies.

Language: Английский

Citations

0